Seeking Alpha

Bloomberg profiles Novartis' (NVS -0.6%) Afinitor drug, which received FDA approval on Friday...

Bloomberg profiles Novartis' (NVS -0.6%) Afinitor drug, which received FDA approval on Friday for use in breast cancer. The treatment, which was already authorized for kidney tumors and organ transplant patients, generated sales of $318M in H1; sales could rise to $2.5B by 2016, forecasts Deutsche Bank's Tim Race.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|